PT  - JOURNAL ARTICLE
AU  - Hao, Yanting
AU  - Zhang, Hua
AU  - Yan, Yingying
AU  - Zhu, Yun
AU  - Zhang, Fuchun
TI  - A Model to Predict In-hospital Mortality in Elderly Patients with Community-acquired Pneumonia: a Retrospective Study
AID  - 10.1101/2022.04.18.22273956
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.04.18.22273956
4099  - http://medrxiv.org/content/early/2022/04/18/2022.04.18.22273956.short
4100  - http://medrxiv.org/content/early/2022/04/18/2022.04.18.22273956.full
AB  - Objectives To develop and validate a predictive model for evaluating in-hospital mortality risk in elderly patients with community-acquired pneumonia.Setting Two tertiary care hospitals with 2000 beds and 1000 beds respectively in Beijing, China.Participants Elderly patients (age ≥ 65 years) with community-acquired pneumonia admitted to the Department of Internal Medicine of the two hospitals from January 2010 to December 2019 or from January 2019 to December 2019 respectively.Design It was a retrospective study. After dividing the data set into training and validation sets, we created a mortality model that included patient demographics, hospitalization time, hospital outcome, and various clinical conditions associated with hospitalization. We then applied the model to the validation set.Main outcome measures In-hospital mortality.Results The training cohort included 2,466 patients admitted to the one hospital, while the validation cohort included 424 patients at the other hospital. The overall in-hospital mortality rate was 15.6%. In the multivariable model, age, respiratory failure, heart failure, and malignant tumors were associated with mortality. The model had excellent discrimination with AUC values of 0.877 and 0.930 in the training and validation cohorts, respectively.Conclusions The predictive model to evaluate in-hospital mortality in elderly patients with community-acquired pneumonia, which was established based on administrative data, provides a simple tool for physicians to assess the prognosis of elderly patients with community-acquired pneumonia in Beijing.Strengths and limitations of this studyThe clinical data collected were obtained from a large retrospective cohort over a 10-year period, resulting in good reliability.The model based on administrative data can help healthcare workers determine the prognosis and outcomes of elderly patients of CAP, especially in resource limited regions in China.Our main outcome was in-hospital mortality, not 30-day mortality or longer.All included cases were collected from inpatient, outpatient and emergency patients were not included.The model was only verified in two hospitals in Beijing and further verification should be conducted in other areas and different levels of hospitals.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was carried out at the Peking University Third Hospital and Beijing Haidian Hospital. The study protocol was approved by the research ethics committee of Peking University Third hospital and complied with the principles of the Declaration of Helsinki(Project No. IRB00006761-M2021422). All data were used anonymously; written informed consent was not required because this was a retrospective study using deidentified clinical information.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDate are available upon reasonable request to corresponding author (e-mail: zhangfuchun8203{at}126.com).